For Clinical Quality leaders, the conversation is changing.
Quality has traditionally been associated with audits, findings, CAPAs and ensuring compliance with regulatory requirements. While these responsibilities remain fundamental, Quality teams are increasingly being asked to contribute much earlier — helping organizations identify risk, make informed decisions and build quality into clinical operations from the outset.
This shift was a recurring theme at the recent Linking Leaders Clinical Quality Roundtable for Small BioPharma, sponsored by ADAMAS Consulting, where senior Quality and Compliance leaders discussed the challenges currently shaping clinical development.
From vendor oversight and ICH E6(R3) implementation to AI governance and inspection readiness, one message came through consistently: Quality delivers greater value when it is proactive, connected to the business and involved before issues escalate.
1. Move Quality upstream
One of the clearest themes from the discussion was the importance of moving from reactive quality management toward prevention.
For Quality teams, this means more than responding effectively when deviations, findings or compliance concerns arise. It means understanding where risks may emerge and helping operational teams address them before they develop into larger issues.
A “do it right the first time” mindset can reduce the need for costly remediation later while strengthening data integrity, patient safety and product quality.
Achieving this requires Quality to be involved early enough to influence decisions — rather than being brought in once a problem has already occurred.
2. Make Quality a visible and approachable partner
The value of Quality depends not only on processes and systems, but also on relationships.
Roundtable participants emphasized the importance of strong alignment between Quality and Clinical Operations, with Quality providing perspective, education and support for operational decision-making.
Quality forums can play an important role in creating that connection. Rather than simply reviewing metrics, effective forums can bring cross-functional teams together to discuss emerging risks, audit status, study issues and areas requiring action.
Participants also highlighted the value of more engaging approaches to Quality communication, from informal fireside chats and drop-in sessions to inspection-readiness exercises and practical case studies.
The objective is not simply to increase Quality’s visibility. It is to create an environment where teams engage Quality early because they see the function as a valuable partner.
3. Strengthen vendor oversight as operating models become more complex
The growing reliance on CROs and specialist vendors makes effective oversight increasingly important.
Roundtable participants emphasized that outsourcing an activity does not mean outsourcing accountability.
Recent inspection experiences discussed during the meeting reinforced this point, with vendor oversight remaining an important area of regulatory scrutiny. Maintaining effective oversight requires sponsors to understand not only whether a vendor is delivering, but also how activities are being performed and where quality risks may be developing.
Several practical principles emerged from the discussion:
As vendor ecosystems become increasingly interconnected, oversight also needs to extend beyond individual vendor relationships toward a more integrated view of risk across the study.
4. Use data to see risk earlier
Effective Quality oversight increasingly depends on visibility.
When quality issues, CAPAs, monitoring findings and vendor performance data remain fragmented across individual studies and systems, patterns can be difficult to identify.
Roundtable participants discussed approaches such as centralized vendor quality dashboards that bring information together across studies and vendors, enabling teams to identify recurring issues and emerging trends.
This is where data-enabled Quality oversight can create significant value.
Rather than relying solely on retrospective reviews, organizations can use quality and operational data to prioritize attention, identify emerging signals and determine where deeper investigation or intervention may be required.
5. Prepare for the next generation of Quality oversight
Technology is adding another dimension to this evolution.
AI is already being explored across Clinical Quality and Operations for activities ranging from knowledge retrieval and document drafting to inspection-readiness support, anomaly detection and safety case triage.
The discussion suggested that the question is increasingly shifting from whether AI should be used to how it should be governed.
For Quality leaders, this introduces new considerations around intended use, validation, human accountability, audit trails, vendor transparency and inspection defensibility.
A risk-based approach will be critical. Controls should be proportionate to how the technology is being used and the potential impact on GxP records, workflows and decisions.
Importantly, Quality does not need to manage this transformation alone. Effective AI governance requires collaboration across Quality, IT, Legal, Digital and operational teams.
Quality as a strategic partner
The role of Clinical Quality is not becoming less focused on compliance. It is becoming broader.
Strong Quality organizations still provide independent oversight and ensure regulatory expectations are met. But they can also help organizations understand risk, challenge assumptions, improve decision-making and prevent issues before they require remediation.
For smaller and growing biopharma organizations in particular, where resources may be constrained and external partners play a significant role in clinical development, access to the right Quality expertise at the right time can make a meaningful difference.
The opportunity is to move Quality upstream — from reviewing what has already happened to helping shape what happens next.
ADAMAS Consulting supports pharmaceutical and biotechnology organizations with risk-based Quality and GxP expertise across the clinical development lifecycle. Explore our Clinical Quality and compliance resources to learn more about building proactive, inspection-ready Quality approaches.
